Ahmet Zehir, PhD

Diagnostics development | Clinical cancer genomics

I am currently the Executive Director, Precision Medicine Innovation at AstraZeneca, in the Precision Medicine and Biosamples function. I lead the strategy for diagnostic portfolio development focusing on near-patient blood-based diagnostics for therapy selection, minimal residual disease assessment and early detection of cancer.

In the past, I have led development bioinformatics analysis pipelines, deep-learning based AI algorithms, web applications for analysis of NGS data and biomarker identification combining clinical and genomic data, enabling me to speak to a wide-range of activities in next-generation diagnostics development. I am passionate about increasing the availability and access to molecular diagnostics for patients and strongly believe every cancer patient can and will benefit from genomic profiling.

I was previously an Associate Professor at the Department of Pathology as well as the Director of Clinical Bioinformatics at the Molecular Diagnostics Service at Memorial Sloan Kettering Cancer Center. I co-led the development and implementation of several tissue and blood based diagnostic assays (eg: MSK-IMPACT and MSK-ACCESS) and led the building of computational infrastructure that enabled high-throughput data analysis, storage and dissemination.

I am also a member of the Molecular Oncology Committee in Collage of American Pathologists and am an elected representative of the informatics subdivision of the Association of Molecular Pathology to the Nominating Committee.